Antivascular agents that act by destabilizing microtubules, such as ZD6126 ( Nacetylcolchinol-O -phosphate), are associated with adverse cardiovascular effects, including transient hypertension, cardiac ischemia, myocardial infarction, and increases in circulating levels of markers of cardiac damage (e.g., troponins). We investigated mechanisms underlying these effects of ZD6126 in rats by continuously monitoring their heart rate and blood pressure and by assessing heart histopathology and plasma troponin T levels. ZD6126 induced acute transient hemodynamic changes (hypertension and delayed tachycardia), which were associated with statistically significant increases in circulating troponin T levels (median level 3 hours after treatment with vehicle or 12.5 mg/kg ZD6126: <9 pg/mL and 563 pg/mL, respectively; P <.001 [two-sided Wilcoxon rank sum test]) and in the incidence of left ventricular myocardial fiber necrosis (incidence 24 hours after treatment with vehicle or 12.5 mg/kg ZD6126: 0/10 rats and 9/10 rats, respectively; P <.001 [twosided Wilcoxon rank sum test]). Pretreatment of rats with atenolol and nifedipine ameliorated the acute hemodynamic changes and prevented ZD6126-induced increases in both troponin T and myocardial necrosis but did not prevent ZD6126-induced tumor necrosis in an Hras5 tumor xenograft model in nude rats. Our findings suggest that ZD6126-induced acute hemodynamic changes are a prerequisite for cardiac damage in rats. Administration of ZD6126 to rats produced a rapid increase in diastolic blood pressure that lasted for 120 -180 minutes, which was accompanied by a more prolonged and complex effect on heart rate ( Fig. 1 ). ZD6126 induced tachycardia that was delayed with respect to the effects on diastolic blood pressure, possibly due, in part, to a refl ex bradycardia resulting from normal homeostatic mechanisms acting to reduce the severity of the concurrent hypertension. When the acute hypertensive response abated 120 -180 minutes after ZD6126 treatment, tachycardia became apparent and persisted for at least an additional 240 minutes. Preliminary experiments showed that direct vasodilation induced by an oral dose of the calcium channel-blocking agent, nifedipine, was effective in abolishing ZD6126-induced hypertension, whereas the ␤ -adrenoceptor antagonist atenolol was effective in limiting ZD6126-induced tachycardia (data not shown). Figure 1 shows that the combination of atenolol and nifedipine, given 1 hour before ZD6126 administration, was effective in abolishing both the hypertensive and tachycardic effects of ZD6126.
medical-grade air and was maintained with 1.5% -2.5% isofl urane throughout the procedure. The abdominal cavity of each rat was opened, and the descending ab dominal aorta was located and cleared of connective tissue. A tie placed underneath the vessel was lifted to occlude the vessel while the catheter of a DSI TA11PA-C40 radiotelemetry implant (Data Sciences International, St Paul, MN) was inserted into the aorta along the bevel of a bent 21-gauge needle. The catheter was held in place by suturing it to the inside of the abdominal wall. The surgical abdominal wound was then closed with dissolving sutures, and the outer skin was closed with autoclips. The rats were allowed to recover from surgery and acclimatized to the handling procedures required for dosing, and they were randomly assigned to one of three groups (n = 3 rats per group). Group 1 (the control group) received 1% polysorbate 80 by mouth at 150 minutes and, 1 hour later (i.e., at 210 minutes), 0.9% sodium chloride solution (physiological saline) by intravenous injection. Time zero (0 minutes) was arbitrarily defi ned as 6:00 am . Group 2 received 1% polysorbate 80 by mouth at 150 minutes and ZD6126 (12.5 mg in physiological saline/kg) by intravenous injection at 210 minutes. Group 3 received atenolol (6 mg/kg) and nifedipine (10 mg/kg) (Sigma -Aldrich, Poole, U.K.), both by mouth at 150 minutes, each in 1% polysorbate 80, and ZD6126 (AstraZeneca) (12.5 mg/kg) by intravenous injection at 210 minutes. Blood pressure and heart rate data were collected via the radiotelemetry implant every 5 minutes beginning at 0 minutes for 24 hours. For each rat, data were collected as a moving point average over a 30-second period within each 5-minute interval.
Vascular disrupting agents selectively destroy the existing tumor vasculature by inducing morphologic changes in tumor endothelial cells that lead to vessel occlusion and massive central tumor necrosis ( 1 -3 ) . ZD6126, a soluble prodrug of Nacetylcolchinol, is a vascular disrupting agent that acts by inhibiting tubulin polymerization, which destabilizes the microtubule network and induces morphologic changes in immature tumor endothelial cells ( 4 -6 ) . Several phase I studies have been carried out to identify the optimal dosing schedule of ZD6126 and to define its tolerability and pharmacokinetic profile ( 7 -9 ) . Dynamic contrast-enhanced magnetic resonance imaging has demonstrated substantially reduced tumor uptake of gadolinium contrast agent in ZD6126-treated mice and patients, a finding that is consistent with the selective vascular disrupting effects of ZD6126 in tumors ( 10 ) . How ever, the phase I studies ( 7 -9 ) reported that ZD6126 treatment was associated with adverse cardiovascular events that generally occurred within a few hours after ZD6126 was administered and comprised one or more of the following: electrocardiogram abnormalities, an increase in the circulating level of troponin I (a marker of cardiac damage), and/or arm or chest pain. ZD6126 treatment is also associated with a transient increase in blood pressure ( 9 ) . Similar adverse cardiac events have been reported for other microtubule-destabilizing vascular disrupting agents that are in clinical development ( 11 -13 ) . In this study, we used a rat preclinical model to examine the underlying mechanisms responsible for the adverse cardiac events associated with ZD6126.
For analyses of ZD6126-induced hemodynamic changes, anesthesia was induced in female Wistar-derived Alpk:ApfSD rats (175 -200 g; n = 9; AstraZeneca, Macclesfi eld, Cheshire, U.K.) with 3% -4% isofl urane (Abbott Laboratories, Chicago, IL) in
Effect of Pretreatment With Atenolol and Nifedipine on ZD6126-Induced Cardiac Toxicity in Rats
Administration of ZD6126 to rats produced a rapid increase in diastolic blood pressure that lasted for 120 -180 minutes, which was accompanied by a more prolonged and complex effect on heart rate ( Fig. 1 ) . ZD6126 induced tachycardia that was delayed with respect to the effects on diastolic blood pressure, possibly due, in part, to a refl ex bradycardia resulting from normal homeostatic mechanisms acting to reduce the severity of the concurrent hypertension. When the acute hypertensive response abated 120 -180 minutes after ZD6126 treatment, tachycardia became apparent and persisted for at least an additional 240 minutes. Preliminary experiments showed that direct vasodilation induced by an oral dose of the calcium channel-blocking agent, nifedipine, was effective in abolishing ZD6126-induced hypertension, whereas the ␤ -adrenoceptor antagonist atenolol was effective in limiting ZD6126-induced tachycardia (data not shown). Figure 1 shows that the combination of atenolol and nifedipine, given 1 hour before ZD6126 administration, was effective in abolishing both the hypertensive and tachycardic effects of ZD6126.
We next examined the effects of the three drugs, alone and in combination, on rat heart histopathology and plasma troponin T levels. Female rats (n = 60) were randomly assigned to one of the following six treatment groups (10 rats per group): physiological saline; ZD6126 (5 mg/kg); ZD6126 (12.5 mg/kg); atenolol (6 mg/kg) and nifedipine (10 mg/kg) alone; atenolol (6 mg/kg) and nifedipine (10 mg/kg) with ZD6126 (5 mg/kg or 12.5 mg/kg). When the three drugs were administered to the same rat, ZD6126 was given 1 hour after atenolol and nifedipine, as described previously. Blood samples (0.8 mL in lithium heparin) collected from each rat via the tail at 3, 6, and 24 hours after saline or ZD6126 dosing were subjected to a Troponin T Stat immunoassay (Roche Diagnostics, Lewes, U.K. ) to determine the concentration
CONTEXT AND CAVEATS

Prior knowledge
Antivascular agents selectively destroy the existing tumor vasculature. However, some vascular disrupting agents in early clinical development that act by destabilizing microtubules, such as ZD6126, are associated with adverse cardiovascular effects.
Study design
A rat preclinical model was used to examine the underlying mechanisms responsible for the adverse cardiac events associated with ZD6126.
Contribution
ZD6126 induces acute hemodynamic changes that are a prerequisite for cardiac damage in rats.
Implications
Clinical investigations of approaches that reduce the acute hemodynamic effects of microtubule-destabilizing vascular disrupting agents are warranted.
Limitations
Not all patients who receive ZD6126 experience cardiovascular adverse events, sug gesting that the underlying biologic mechanisms in patients may differ from those in rats. The direct relevance of this rat model to patients treated with ZD6126 is unclear. Effects of atenolol and nifedipine on the hemodynamic changes induced by ZD6126. Heart rate and blood pressure were monitored continuously by telemetry (beginning at 0 minutes) in three groups of rats (n = 3 per group). The control group received two vehicles, 1% polysorbate 80 by mouth (at 150 minutes) and, 1 hour later (at 210 minutes), 0.9% physiological saline by intravenous injection. The ZD6126 group received 1% polysorbate 80 by mouth (at 150 minutes) and, 1 hour later (at 210 minutes), ZD6126 (12.5 mg/kg) by intravenous injection. The atenolol, nifedipine, ZD6126 group received atenolol (6 mg/kg) and nifedipine (10 mg/kg), both by mouth (at 150 minutes), and, 1 hour later (at 210 minutes), ZD6126 (12.5 mg/kg) by intravenous injection. Mean blood pressure ( A ) and heart rate ( B ) data are shown .
of troponin T. Samples with values at or below the lower limit of detection for the assay (9 pg/mL) were recorded as 9 pg/mL. Data were analyzed for each time point compared with vehicle-treated control rats using a Wilcoxon rank sum test. All rats were subjected to terminal anesthesia by halothane inhalation 24 hours after saline or ZD6126 dosing, and their hearts were removed, fi xed by immersion in neutral phosphate-buffered formalin, and bisected so that left and right ventricular and atrial tissues were present in both samples. Both halves of each heart were processed together and embedded in wax blocks.
Step sections Table 1 . Heart histopathology and plasma troponin T levels in rats treated with ZD6126 alone or in combination with atenolol and nifedipine * (5 µ m) were taken at 300-µ m intervals. Five hematoxylin-eosin -stained sections were prepared from each block for examination by light microscopy. The sections were examined in a blinded fashion by a pathologist (F. R. Westwood ) for myocardial necrosis and associated histopathologic changes (i.e., hemorrhage and mixed infl ammatory cell infi ltration/fi broplasia), which were graded semiquantitatively as follows: minimal (a single or a few small areas); mild (up to 20% of a region of myocardium affected); moderate (more than 20% up to 50% of the myocardium affected); or severe (more than 50% of the myocardium affected). For each rat heart, the most severe change on any of the fi ve step sections for each of the right and left ventricles (10 sections in total) was recorded for each of the histopathologic parameters. For statistical analysis of left ventricle necrosis data, each grade of histopathologic change was assigned a score of 1 -4, where no change = 1, minimal change = 2, mild change = 3, and moderate change = 4.
(No severe changes were seen in these experiments.) The scores for the hearts from rats within a treatment group were compared with the scores for vehicle-treated control rats using a Wilcoxon rank sum test. All statistical tests were two-sided.
Compared with hearts from vehicletreated control rats, hearts from rats 24 hours after dosing with ZD6126 at 5 or 12.5 mg/kg showed a statistically signifi cantly higher incidence of mild or moderate left ventricular myocardial necrosis (median scores in control, 5 mg/kg ZD6126, and 12.5 mg/kg ZD6126 groups were 1, 2.5, and 3, respectively; P <.001) and a higher incidence of left ventricular hemorrhage and mixed cell infi ltration/fi broplasia ( Table 1 ) . Similar histopathologic changes (i.e., necrosis, hemorrhage, and mixed cell infi ltration/ fi broplasias) were seen in the right ventricle, although these appeared to be less severe. Similar data were obtained for hearts evaluated 72 hours after dosing and for rats given higher doses (up to 50 mg/kg) of ZD6126 (Supplementary Table 1 , available online).
Histopathologic examination revealed that pretreatment of rats with atenolol and nifedipine before ZD6126 abolished all myocardial damage at both the 5 and 12.5 mg/kg doses of ZD6126 ( Table 1 ) . The single occurrence of minimal ventricular myocardial necrosis seen following administration of ZD6126 at 12.5 mg/kg after atenolol and nifedipine could not be clearly attributed to the administration of ZD6126 because it was observed in only one necrotic fi ber in only one of 10 sections assessed. By contrast, the minimal necrosis we observed in the heart of one control rat involved multiple fi bers.
Rats treated with ZD6126 at 5 or 12.5 mg/kg had statistically signifi cantly higher median troponin T levels at 3 hours after ZD6126 treatment compared with vehicletreated control rats (control = 9 pg/mL, 5 mg/kg ZD6126 = 274 pg/mL, and 12.5 mg/kg ZD6126 = 563 pg/mL; P <.001). Testing of a broad range of ZD6126 doses (2.5 -50 mg/kg) in rats indicated a statistically signifi cant dose-related increase in plasma troponin T levels 3 hours after treatment (Supplementary  Table 2 , available online). Troponin T levels remained elevated 6 hours after treatment with ZD6126, but by 24 hours after treatment, the levels decreased to those seen in plasma from vehicle-treated control rats ( Table 1 ) . However, pretreatment of rats with atenolol and nifedipine fully prevented the increases in troponin T seen at 3 hours after ZD6126 treatment ( Table 1 ) .
At the onset of these studies, we cons idered three potential mechanisms for ZD6126-induced myocardial necrosis to be feasible: 1) by direct and selective morphologic and/or cytotoxic effects on cardiac endothelial cells, because the endothelium, at least in tumors, is a proven target of ZD6126; 2) by direct cytotoxic effects on the myocardium; or 3) as a consequence of the induced acute hemodynamic alterations. We ruled out a direct effect of ZD6126 on cardiac endothelial cells because detailed histopathologic evaluation of rat hearts isolated 2 hours after treatment with ZD6126 at a dose of 12.5 mg/kg using either 0.75-µ m thick tissue sections stained with toluidine blue or an antibody against the endothelial cell marker CD31 showed no evidence of morphologic or histologic changes in endothelial cells preceding the myocardial necrosis (data not shown). This fi nding is in sharp contrast to the effect of ZD6126 on tumor vessels, in which endothelial cell damage has been found to precede tumor cell necrosis ( 6 ) . We also ruled out the possibility that ZD6126 had direct cytotoxic effects on the myocardium because the myocardial necrosis we observed was localized rather than diffuse (data not shown).
Because pretreatment with atenolol and nifedipine prevented ZD6126-induced cardiac necrosis and increased plasma troponin T levels but had no marked effects on the plasma levels of ZD6126 phenol (the active form of ZD6126) (Supplementary  Table 3 , available online), we conclude that the ZD6126-induced myocardial necrosis in the rat is secondary to ZD6126-induced hemodynamic changes.
The cardiac necrosis we observed in ZD6126-treated rats was most commonly seen in the subendocardial to mid-left ventricular wall areas, which include the papillary muscles. This distribution is similar to that induced by hypoxia and isoprenalin, which shortens the diastolic period when ventricular blood perfusion is maximal ( 14 ) . The cardiac changes induced by ZD6126 could be due to an imbalance between myocardial oxygen delivery and oxygen demand that results in inadequate myocardial perfusion, which is analogous to the situation in which diastolic fi lling time, during which the blood irrigates myocardial tissue, is shortened due to tachycardia and coronary artery perfusion pressure is reduced due to systemic hypotension ( 15 , 16 ) . We hypothesize that acute vasoconstriction that is accompanied by tachycardia, as we have seen in rats following ZD6126 administration, may produce a similar inadequacy in myocardial perfusion, whereby tachycardia exacerbates hemodynamic changes associated with vasoconstriction.
The mechanism of cardiac toxicity suggested by this study (i.e., acute vasoconstriction/hypertension accompanied by tachycardia) is unlikely to be unique to ZD6126 because other tubulin-binding vascular disrupting agents (i.e., combretastatin A4 phosphate and AVE8062) are reported to have similar cardiac effects in the clinic ( 7 -9 ) and because we have observed a similar pattern of cardiac necrosis after treating rats with combretastatin A4 phosphate (data not shown). Although the underlying mechanisms responsible for ZD6126-induced acute hypertension and tachycardia remain unknown, other microtubule-destabilizing agents (i.e., colchicine, nocodazole, and demecolcine) have been shown to induce vasoconstriction through their effects on vascular smooth muscle tone ( 17 ) .
To investigate the effects of pretreatment with atenolol and nifedipine on the antitumor effi cacy of ZD6126, we measured tumor necrosis in a tumor xenograft model in nude rats. Athymic female rats (HsdHan:Rnu-rnu; 100 -160 g; n = 24; AstraZeneca, Alderley Park, U.K.) were implanted subcutaneously with Hrastransformed mouse 3T3 fi broblasts (Hras5 cells; 2 × 10 5 cells per rat) ( 6 ) . When Hras5 xenograft tumors reached a size of ap proximately 0.5 cm 3 , the rats were randomly assigned to one of six treatment groups (n = 4 rats per group): physiological saline and 1% polysorbate 80; atenolol (6 mg/kg) and nifedipine (10 mg/kg); ZD6126 (5 or 12.5 mg/kg); atenolol (6 mg/kg) and nifedipine (10 mg/kg) plus ZD6126 (5 or 12.5 mg/kg). When all three agents were administered to the same rat, atenolol and nifedipine were given 1 hour before ZD6126. Rats were killed 24 hours after ZD6126 or vehicle dosing and their tumors excised, fi xed in 10% neutral-buffered formalin, and processed for embedding in wax blocks. Necrosis was assessed by light microscopy in sections (4-µ m thick) that were stained with hematoxylin -eosin. For each tumor, necrosis was assessed in a single section cut from the widest part of the tumor with the use of operator-guided image analysis software (KS400 version 3.0 image analysis system; Carl Zeiss Vission GmbH, Hallbergmoos, Germany). For each treatment group, the mean percentage of necrotic cells and the 95% confi dence interval (CI) was calculated.
ZD6126 induced extensive tumor necrosis in Hras5 xenografts 24 hours after dosing (necrotic fraction of cross-sectional tumor area at 5 and 12.5 mg/kg = 32% and 87%, respectively) ( Table 2 ) , consistent with results from a previous study ( 4 This small study has several limitations. In the clinic, only a minority of patients experience cardiovascular adverse events following ZD6126 treatment. By contrast, in the rat models used here the response to ZD6126 dosing was more homogeneous, and almost all animals displayed both increases in plasma troponin T level and histopathologically confi rmed cardiac damage at ZD6126 dose levels of 5.0 mg/kg or higher. The factors that differentiate patients at risk for cardiovascular adverse events following ZD6126 dosing are not known, but extending the current studies to different strains of rat may help identify the underlying biologic mechanisms. In addition, the mechanism of ZD6126-induced tachycardia seen in rats is unclear but is likely to be indirect because no effect of ZD6126 on heart rate has been observed in isolated perfused rat hearts (data not shown). Further work is required to understand whether tachycardia observed in this rat model is relevant to patients treated with ZD6126.
In conclusion, our data in rats suggest that the adverse cardiac events observed in the clinic following ZD6126 administration may result, at least in part, from acute hemodynamic changes. This conclusion has potential therapeutic implications because our studies also suggest that these acute hemodynamic changes, and the subsequent cardiac side effects, may be ameliorated by antihypertensive therapy without overtly affecting the antitumor effi cacy of ZD6126.
